Israel’s Kadimastem is partnering with France’s Defymed to develop a stem cell-based bio-artificial pancreas for the treatment of type 1 diabetes. They received NIS 5.4 million from the European Commission and the intergovernmental research organization EUREKA.
https://www.calcalistech.com/ctech/articles/0,7340,L-3749642,00.html